Atopic dermatitis: Tofacitinib, an option for refractory disease

Abstract

Abstract Atopic dermatitis (AD) is a common skin disease, associated with high burden impact in quality of live, in moderate‐severe disease severity. Several targeted drugs are under development for AD. Here, we present a patient with refractory disease to systemic traditional immunosuppressive drugs, treated successfully with oral tofacitinib, with complete response.

Keywords

• atopic dermatitis
• dermatology
• eczema
• JAK inhibitors
• tofacitinib